Core Viewpoint - ODDITY Tech Ltd. is facing a class action lawsuit due to significant financial losses attributed to issues with its largest advertising partner, leading to a sharp decline in stock price and increased customer acquisition costs [2][3]. Financial Performance - On February 25, 2026, ODDITY reported its fourth quarter and full year 2025 financial results, indicating a 30% expected decline in revenue year-over-year for the first quarter of 2026 [2]. - The company's stock price plummeted by $14.28, or 49.2%, closing at $14.74 per share following the announcement of these results [3]. Lawsuit Details - The class action lawsuit alleges that ODDITY made materially false and misleading statements regarding its business operations and financial health during the class period from February 26, 2025, to February 24, 2026 [3]. - Key allegations include failure to disclose the impact of an algorithm change by its largest advertising partner, which led to higher customer acquisition costs and negatively affected the company's market position [3].

Core Viewpoint - Beyond Meat, Inc. is facing a securities fraud lawsuit, with a lead plaintiff deadline set for March 24, 2026, for investors who purchased securities during the specified class period [1]. Group 1: Lawsuit Details - The lawsuit claims that during the class period, Beyond Meat made materially false and misleading statements regarding the valuation of its long-lived assets, which exceeded their fair value, leading to a likely non-cash impairment charge [5]. - The lawsuit also alleges that these misstatements impaired Beyond Meat's ability to file periodic reports with the Securities and Exchange Commission in a timely manner [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in recovering significant amounts for investors [4]. - Investors wishing to serve as lead plaintiffs must file a motion with the court by the deadline of March 24, 2026 [3]. - Until a class is certified, investors are not represented by counsel unless they retain one, and they have the option to remain absent from the class [7].

Core Viewpoint - Immutep Ltd. is facing a securities fraud lawsuit after allegedly misrepresenting the progress of its Phase III TACTI-004 trial, leading to significant losses for investors when the trial was halted due to failure to meet efficacy endpoints [1][2][3]. Group 1: Trial Progress and Misrepresentation - On January 30, 2026, Immutep reported that the futility analysis for the TACTI-004 trial was "on track" and described "strong operational progress" [2]. - Just six weeks later, on March 13, 2026, the Independent Data Monitoring Committee (IDMC) recommended halting the trial after determining it was unlikely to meet its primary efficacy endpoints [2][3]. - The lack of public disclosure regarding any changes in the trial's outlook between the January 30 filing and the March 13 announcement raised concerns among investors [3]. Group 2: Financial Impact - Following the IDMC's recommendation to halt the trial, Immutep's stock price collapsed by approximately 80-90% in a single session [1][3]. - The TACTI-004 trial was considered the company's lead oncology asset, making the impact of the trial's failure particularly significant for shareholders [3].

Core Viewpoint - The article discusses an ongoing securities fraud lawsuit against monday.com Ltd. (MNDY) due to significant stock price declines following misleading financial projections and performance disclosures [2][3]. Group 1: Financial Performance and Stock Impact - On November 10, 2025, monday.com reported third-quarter revenue of $316.9 million but projected only modest revenue growth for the fourth quarter, leading to a stock price drop of $23.38, or 12.3%, closing at $166.21 per share [2]. - On February 9, 2026, the company rescinded its $1.8 billion revenue target for fiscal year 2027 and indicated a significant deceleration in growth for 2026, causing the stock price to fall by $20.37, or 20.8%, to close at $77.63 per share [3]. Group 2: Allegations in the Lawsuit - The lawsuit alleges that during the class period, the defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and growth prospects [3]. - Specific allegations include the deceleration of new customer growth, weaker expansion within existing accounts, and longer enterprise sales cycles, which made the $1.8 billion revenue target increasingly unlikely to be met [3].

Core Viewpoint - Trip.com Group Limited (TCOM) is facing a class action lawsuit due to allegations of securities fraud related to antitrust investigations by Chinese regulators, which resulted in a significant drop in stock price [2][3]. Group 1: Lawsuit Details - The lawsuit is based on claims that Trip.com made materially false and misleading statements regarding its business operations and regulatory risks during the class period from April 30, 2024, to January 13, 2026 [3]. - The lawsuit alleges that Trip.com failed to disclose the regulatory risks associated with its monopolistic practices, leading to misleading positive statements about the company's prospects [3]. Group 2: Stock Price Impact - Following the news of the antitrust investigation on January 14, 2026, Trip.com's stock price fell by $12.90, or 17.05%, closing at $62.78 per share [2]. Group 3: Legal Participation - Investors who purchased Trip.com securities during the class period are encouraged to file a lead plaintiff motion by the deadline of May 11, 2026, to participate in the lawsuit [4].

Core Viewpoint - Corcept Therapeutics faces a class action lawsuit following a significant drop in stock price after the FDA declined to approve its New Drug Application for relacorilant, citing insufficient evidence of effectiveness [2][3]. Company Overview - Corcept Therapeutics Incorporated (NASDAQ: CORT) is involved in the development of treatments for conditions related to cortisol, specifically hypercortisolism [1]. FDA Response - On December 31, 2025, the FDA issued a Complete Response Letter (CRL) for Corcept's NDA for relacorilant, stating it could not make a favorable benefit-risk assessment without additional evidence [2]. - The stock price of Corcept fell by $35.40 per share, or 50.42%, closing at $34.80 on the same day [2]. Class Action Details - The class action lawsuit alleges that Corcept made materially false and misleading statements regarding the adequacy of its clinical development program and the FDA's concerns about relacorilant [3]. - Specific allegations include failure to disclose the FDA's concerns about the pivotal "GRACE" trial and expectations of significant review issues if the NDA was submitted [3]. Legal Proceedings - Investors who purchased Corcept common stock during the Class Period (October 31, 2024, to December 30, 2025) have until April 21, 2026, to file a lead plaintiff motion in the class action [1][4].

Core Viewpoint - The article highlights the upcoming deadline of April 3, 2026, for investors to file a lead plaintiff motion in a class action lawsuit concerning Picard Medical, Inc. (NYSE American: PMI) securities, which were acquired between September 2, 2025, and October 31, 2025 [1]. Group 1 - The class action is filed on behalf of investors who purchased or acquired Picard Medical securities during the specified class period [1]. - Investors who suffered losses on their Picard investments are encouraged to inquire about potential participation in the lawsuit [1].

Core Viewpoint - The Law Offices of Frank R. Cruz is reminding investors about the January 26, 2026 deadline to participate as lead plaintiffs in a securities fraud class action lawsuit against Sprouts Farmers Market, Inc. for losses incurred during the specified class period [1] Group 1 - The lawsuit is on behalf of investors who acquired Sprouts Farmers Market, Inc. securities between June 4, 2025, and October 29, 2025 [1] - The company is listed on NASDAQ under the ticker symbol SFM [1]

Core Viewpoint - Bitdeer Technologies Group is facing a class action lawsuit due to significant financial losses and misleading statements regarding its product development, particularly the Seal 04 ASIC chip [2][4]. Financial Performance - On November 10, 2025, Bitdeer reported a per-share loss of $1.28 for Q3 2025, which was significantly worse than the expected loss of $0.22 [2]. - Following the announcement, Bitdeer's stock price dropped by $2.63, or 14.9%, closing at $15.02 per share on November 11, 2025, impacting investors negatively [3]. Lawsuit Details - The class action lawsuit alleges that Bitdeer made materially false and misleading statements and failed to disclose adverse facts about its business and operations during the class period from June 6, 2024, to November 10, 2025 [4]. - Specifically, the lawsuit claims that Bitdeer misrepresented the readiness and efficiency of the SEAL04 chip, which was projected to have a chip-level energy efficiency of 5 J/TH and was expected to begin mass production in Q2 2025 [4]. Investor Actions - Investors who purchased Bitdeer securities during the class period can file a lead plaintiff motion by February 2, 2026, to participate in the class action lawsuit [5].

Core Viewpoint - Bath & Body Works, Inc. is facing a class action lawsuit due to significant declines in financial performance and misleading statements regarding its business strategy during the class period from June 4, 2024, to November 19, 2025 [1][7]. Financial Performance - On August 28, 2025, Bath & Body Works reported Q2 2025 earnings per diluted share of $0.30, a decline of 55.8% year over year, and net income of $64 million, down 57.9% year over year [3]. - The company cut its full-year guidance for earnings per diluted share by $0.03, adjusting it to a range of $3.28 to $3.53 [3]. - On November 20, 2025, the company reported Q3 2025 revenue declined by 1% year over year, missing guidance of 1-3% growth, and net income fell 26% to $77 million [5]. - The full-year guidance for net sales was slashed from a previously positive 1.5%-2.7% to a negative "high single digits," and expected earnings per diluted share were reduced to "at least $2.83" [5]. Stock Performance - Following the Q2 2025 results announcement, Bath & Body Works' stock price fell by $2.18, or 6.9%, closing at $29.36 per share on August 28, 2025 [4]. - After the Q3 2025 results, the stock price dropped by $5.22, or 24.8%, closing at $15.82 per share on November 20, 2025 [6]. Lawsuit Details - The class action lawsuit alleges that the company made materially false and misleading statements and failed to disclose adverse facts about its business and operations [7]. - Specific allegations include the failure of the company's strategy of "adjacencies, collaborations and promotions" to grow the customer base and the reliance on brand collaborations to mask weak financial results [7]. - The lawsuit claims that the company was unlikely to meet its previously issued financial guidance due to these issues [7]. Participation in the Lawsuit - Investors who purchased Bath & Body Works securities during the class period can file a lead plaintiff motion by March 16, 2026, if they meet certain legal requirements [8].